HLN250117C7500
- 2.26
- 0.000.00%
Haleon Newsroom
Haleon Closes Purchase of Additional Stake in Chinese Pharmaceutical JV
Tianjin Pharmaceutical Completes Equity Disposal to Haleon
Haleon PLC (HLN) Receives a Buy From Barclays
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
AlphaValue/Baader Europe Downgrades Haleon to Reduce
BlackRock Adjusts Stake in Haleon PLC
Haleon PLC: Bergin Is Currently CFO of J Sainsbury
Haleon PLC: Bergin Will Join the Board on Feb. 24
Haleon PLC Appoints Blathnaid Bergin as an Independent Non-Executive Director
Haleon PLC: Decision Follows Reduction of Pfizer's Shareholding in Haleon Below 20%
Haleon PLC: Denton Is a Non-Executive Director, Representative of Pfizer
Haleon PLC: David Denton Stepped Down From the Board
Haleon PLC Announces Strategic Board Changes
Haleon Appoints Sta-Romana as Chief Customer Officer for Its U.S. Business
Haleon Price Target Raised to 310 GBp From 300 GBp at JPMorgan
Can Mixed Financials Have A Negative Impact on Haleon Plc's 'S (LON:HLN) Current Price Momentum?
Haleon Aligns Executive Incentives With Shareholders
Haleon PLC Sees Increase in BlackRock's Stake
Argus Research Maintains Haleon(HLN.US) With Buy Rating, Raises Target Price to $11.5
Haleon Recent Weakness a Buying Opportunity, Says Argus